NYSE:ZYME - Zymeworks Stock Price, News & Analysis

$24.99
+0.29 (+1.17 %)
(As of 08/25/2019 04:00 PM ET)
Today's Range
$24.02
Now: $24.99
$25.19
50-Day Range
$22.43
MA: $24.24
$26.77
52-Week Range
$10.72
Now: $24.99
$27.19
Volume116,022 shs
Average Volume173,124 shs
Market Capitalization$979.11 million
P/E RatioN/A
Dividend YieldN/A
Beta1.47
Zymeworks Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The company's lead product candidates include ZW25, a bispecific antibody that is in Phase I clinical trial for the treatment of breast and gastric cancer; ZW49, a bispecific antibody-drug conjugate that is in preclinical stage for treating breast and gastric cancers, and solid tumors. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Previous SymbolNASDAQ:ZYME
CUSIPN/A
Phone604-678-1388

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$53.02 million
Book Value$8.53 per share

Profitability

Net Income$-36,560,000.00
Net Margins-102.78%

Miscellaneous

Employees180
Market Cap$979.11 million
Next Earnings Date11/5/2019 (Estimated)
OptionableOptionable

Receive ZYME News and Ratings via Email

Sign-up to receive the latest news and ratings for ZYME and its competitors with MarketBeat's FREE daily newsletter.


Zymeworks (NYSE:ZYME) Frequently Asked Questions

What is Zymeworks' stock symbol?

Zymeworks trades on the New York Stock Exchange (NYSE) under the ticker symbol "ZYME."

How were Zymeworks' earnings last quarter?

Zymeworks Inc (NYSE:ZYME) posted its quarterly earnings data on Friday, August, 2nd. The company reported ($0.89) EPS for the quarter, missing the consensus estimate of ($0.83) by $0.06. The business had revenue of $7.88 million for the quarter, compared to the consensus estimate of $7.25 million. Zymeworks had a negative return on equity of 24.44% and a negative net margin of 102.78%. View Zymeworks' Earnings History.

When is Zymeworks' next earnings date?

Zymeworks is scheduled to release their next quarterly earnings announcement on Tuesday, November 5th 2019. View Earnings Estimates for Zymeworks.

What price target have analysts set for ZYME?

5 brokerages have issued 1-year target prices for Zymeworks' shares. Their forecasts range from $23.00 to $42.00. On average, they anticipate Zymeworks' stock price to reach $31.60 in the next year. This suggests a possible upside of 26.5% from the stock's current price. View Analyst Price Targets for Zymeworks.

What is the consensus analysts' recommendation for Zymeworks?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zymeworks in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Zymeworks.

Has Zymeworks been receiving favorable news coverage?

Media headlines about ZYME stock have been trending positive recently, InfoTrie Sentiment reports. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Zymeworks earned a daily sentiment score of 2.5 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 6.0 out of 10, meaning that recent media coverage is somewhat likely to have an impact on the stock's share price in the near future. View News Stories for Zymeworks.

Are investors shorting Zymeworks?

Zymeworks saw a increase in short interest in July. As of July 15th, there was short interest totalling 627,000 shares, an increase of 217.6% from the June 15th total of 197,400 shares. Based on an average daily volume of 284,000 shares, the days-to-cover ratio is currently 2.2 days. Approximately 2.8% of the shares of the company are short sold. View Zymeworks' Current Options Chain.

Who are some of Zymeworks' key competitors?

What other stocks do shareholders of Zymeworks own?

Who are Zymeworks' key executives?

Zymeworks' management team includes the folowing people:
  • Dr. Ali Tehrani, Co-Founder, Pres, CEO & Director (Age 47)
  • Mr. Neil A. Klompas C.A., CPA, CPA, CA, Chief Financial Officer (Age 47)
  • Dr. Anthony J. Polverino, Chief Scientific Officer & Exec. VP of Early Devel. (Age 56)
  • Dr. Diana F. Hausman, Chief Medical Officer (Age 56)
  • Dr. Surjit Dixit, VP of Technology (Age 46)

When did Zymeworks IPO?

(ZYME) raised $65 million in an initial public offering (IPO) on Friday, April 28th 2017. The company issued 4,500,000 shares at $13.00-$16.00 per share. Citigroup, Barclays, Wells Fargo Securities and Canaccord Genuity acted as the underwriters for the IPO and Cormark Securities was co-manager.

Who are Zymeworks' major shareholders?

Zymeworks' stock is owned by a number of of institutional and retail investors. Top institutional investors include Camber Capital Management LP (6.64%), Perceptive Advisors LLC (6.05%), Farallon Capital Management LLC (4.48%), Vivo Capital LLC (3.71%), Renaissance Technologies LLC (0.85%) and Price T Rowe Associates Inc. MD (0.77%). Company insiders that own Zymeworks stock include Ali Tehrani, David Kai Yuen Poon, Eli & Co Lilly and Neil A Klompas. View Institutional Ownership Trends for Zymeworks.

Which institutional investors are selling Zymeworks stock?

ZYME stock was sold by a variety of institutional investors in the last quarter, including Wedge Capital Management L L P NC, Granite Investment Partners LLC, Wells Fargo & Company MN, SG Americas Securities LLC and Citadel Advisors LLC. Company insiders that have sold Zymeworks company stock in the last year include Ali Tehrani, David Kai Yuen Poon, Eli & Co Lilly and Neil A Klompas. View Insider Buying and Selling for Zymeworks.

Which institutional investors are buying Zymeworks stock?

ZYME stock was purchased by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Vivo Capital LLC, Camber Capital Management LP, Price T Rowe Associates Inc. MD, D. E. Shaw & Co. Inc., Sofinnova Investments Inc., Farallon Capital Management LLC and Taylor Wealth Management Partners. View Insider Buying and Selling for Zymeworks.

How do I buy shares of Zymeworks?

Shares of ZYME can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Zymeworks' stock price today?

One share of ZYME stock can currently be purchased for approximately $24.99.

How big of a company is Zymeworks?

Zymeworks has a market capitalization of $979.11 million and generates $53.02 million in revenue each year. The company earns $-36,560,000.00 in net income (profit) each year or ($1.26) on an earnings per share basis. Zymeworks employs 180 workers across the globe.View Additional Information About Zymeworks.

What is Zymeworks' official website?

The official website for Zymeworks is http://www.zymeworks.com/.

How can I contact Zymeworks?

Zymeworks' mailing address is 540-1385 WEST 8TH AVENUE, Vancouver A1, V6H 3V9. The company can be reached via phone at 604-678-1388 or via email at [email protected]


MarketBeat Community Rating for Zymeworks (NYSE ZYME)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  179 (Vote Outperform)
Underperform Votes:  145 (Vote Underperform)
Total Votes:  324
MarketBeat's community ratings are surveys of what our community members think about Zymeworks and other stocks. Vote "Outperform" if you believe ZYME will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZYME will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/25/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel